Form 8.3 - Horizon Therapeutics plc

LONDON--()-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

23rd August 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

4,152,613

(1.814%)

47

(0.000%)

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

1,737,700

(0.759%)

1,942,300

(0.848%)

Total

5,890,313

(2.573%)

1,942,347

(0.848%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Ap20

  1. DEALINGS (Note 4)

(a) Purchases and sales

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (USD) (Note 5)

Purchase

105

105.06

Purchase

21

106.00

Purchase

40

105.58

Sale

595

106.12

Purchase

20

105.50

Purchase

20

105.31

Purchase

10

105.98

Purchase

55

105.57

Purchase

57

105.70

Purchase

33

105.23

Purchase

67

105.72

Purchase

20

105.79

Purchase

3

106.13

Purchase

1,009

106.12

Purchase

10

105.43

Sale

3,075

105.81

Sale

530

106.22

Purchase

15

106.18

Purchase

631

105.27

Purchase

531

105.06

Purchase

15,000

105.55

Purchase

756

105.15

Purchase

2,000

105.46

Purchase

1,694

105.10

Purchase

100

105.07

Purchase

105

105.03

Purchase

117

105.08

Purchase

110

105.05

Purchase

9

105.51

Purchase

210

105.53

Purchase

100

105.97

Purchase

6,485

105.45

Sale

400

106.00

Purchase

80

105.58

Purchase

95

106.13

Purchase

1,321

106.12

Sale

24

106.12

Purchase

20

105.50

Purchase

230

105.54

Sale

1,100

106.02

Purchase

135

105.78

Purchase

297

105.16

Purchase

758

105.30

Purchase

10

105.31

Purchase

53

105.12

Sale

612

106.06

Sale

300

106.04

Sale

100

106.01

Purchase

160

105.44

Purchase

200

105.61

Purchase

100

105.43

Purchase

175

105.39

Purchase

100

105.59

Purchase

9

105.13

Purchase

3,075

105.81

Sale

600

105.99

Sale

25

106.11

Purchase

120

105.40

Purchase

200

105.20

Purchase

843

105.64

Sale

245

106.03

Purchase

1,513

106.14

Purchase

148

106.10

Sale

1

106.10

Purchase

100

105.72

Purchase

200

105.75

Purchase

472

105.48

Purchase

530

106.22

Purchase

279

106.16

Sale

11

106.16

Sale

3

106.05

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

 

 

 

 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Call Option

Selling

46,000

110.00

American

15/09/2023

 

Call Option

Selling

100

115.00

American

1/19/2024

 

Put Option

Purchased

1,500

95.00

American

10/20/2023

 

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

24th August 2023

Contact name

Stephen Glasper

Telephone number

+44 203 398 2166

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

(USD)

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Put Option

Purchased

300

80.00

American

1/17/2025

IE00BQPVQZ61

Put Option

Purchased

100,300

90.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

284,900

60.00

American

12/15/2023

IE00BQPVQZ61

Put Option

Written

100,000

65.00

American

7/21/2023

IE00BQPVQZ61

Put Option

Purchased

55,000

70.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

41,500

45.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

250,000

85.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

152,500

110.00

American

17/11/2023

IE00BQPVQZ61

Call Option

Purchased

4,500

110.00

American

10/20/2023

IE00BQPVQZ61

Call Option

Purchased

100,000

100.00

American

12/15/2023

IE00BQPVQZ61

Call Option

Written

100,000

110.00

American

12/15/2023

IE00BQPVQZ61

Call Option

Written

3,400

100.00

American

10/20/2023

IE00BQPVQZ61

Call Option

Purchased

2,800

100.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Written

50,000

85.00

American

15/09/2023

IE00BQPVQZ61

Put Option

Purchased

150,000

85.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Purchased

2,600

90.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Purchased

40,900

100.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Purchased

41,500

65.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

600

100.00

American

10/20/2023

IE00BQPVQZ61

Put Option

Purchased

100,000

70.00

American

17/11/2023

IE00BQPVQZ61

Call Option

Purchased

300

100.00

American

15/09/2023

IE00BQPVQZ61

Put Option

Purchased

300

100.00

American

15/09/2023

IE00BQPVQZ61

Put Option

Written

100,000

60.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

35,000

110.00

American

15/09/2023

IE00BQPVQZ61

Call Option

Purchased

535,200

110.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Written

554,800

115.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

219,800

90.00

American

15/09/2023

IE00BQPVQZ61

Call Option

Purchased

18,000

105.00

American

15/09/2023

IE00BQPVQZ61

Call Option

Written

400

105.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Written

400

105.00

American

17/11/2023

IE00BQPVQZ61

Put Option

Written

312,000

70.00

American

10/20/2023

IE00BQPVQZ61

Put Option

Purchased

323,000

95.00

American

10/20/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET
Sequence Number: 1156716
Time of Receipt (offset from UTC): 20230824T145030+0100

Contacts

Millennium Partners, L.P.

Contacts

Millennium Partners, L.P.